Asia FX dithers as dollar steadies before Powell speech; yen muted after CPI data
Cecil D. Haney, a director at Tenet Healthcare Corp (NYSE:THC), a $12 billion healthcare provider with a notably low P/E ratio of 3.8 and an overall GREAT financial health score according to InvestingPro, has recently reported a sale of company stock. According to a filing with the Securities and Exchange Commission, Haney sold 2,500 shares of Tenet Healthcare on March 4, 2025, at a price of $124.26 per share. This transaction totaled $310,650. Following this sale, Haney retains ownership of 12,035 shares in the company. The sale was reported to have been executed directly by Haney. With analysts setting price targets ranging from $134 to $217, InvestingPro subscribers can access 8 more exclusive insights about THC’s valuation and growth prospects.
In other recent news, Tenet Healthcare’s financial performance and strategic positioning have been the focus of several analyst reports. The company recently reported fourth-quarter results that exceeded expectations, with adjusted EBITDA excluding non-controlling interest reaching $793 million, surpassing projections from Raymond (NSE:RYMD) James. Additionally, Tenet’s adjusted earnings per share came in at $3.44, higher than the consensus estimate of $2.95. Analysts at Raymond James maintained an Outperform rating but lowered the price target to $185, noting Tenet’s strong secular drivers in its Ambulatory Surgery Center business.
Truist Securities reiterated a Buy rating for Tenet Healthcare with a $175 price target, citing solid demand trends and effective debt reduction measures as positive factors. Similarly, TD Cowen initiated coverage with a Buy rating and a $175 target, highlighting Tenet’s successful divestitures and operational improvements. Cantor Fitzgerald maintained an Overweight rating with a $177 target, despite noting challenges due to policy uncertainties in 2025.
KeyBanc Capital Markets also reiterated an Overweight rating with a $185 target, emphasizing Tenet’s strong fourth-quarter performance and ongoing debt reduction efforts. Despite these positive evaluations, concerns about potential policy changes affecting Medicaid funding have been noted as influencing investor sentiment. Overall, these developments reflect continued confidence in Tenet Healthcare’s strategic direction and financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.